Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and cis-C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case report

Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and cis-C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case report

Jing Zhao,1 Ming Zou,1 Jinyan Lv,2 Yingmin Han,1 Guangzhi Wang,3 Gang Wang2 1Department of Pharmacy, Affiliated Zhongshan Hospital of Dalian University, Dalian, People’s Republic of China; 2Department of Oncology, Affiliated Zhongshan Hospital of Dalian University, Dalian, People&rsqu...

Full description

Bibliographic Details
Main Authors:	Zhao J, Zou M, Lv J, Han Y, Wang G
Format:	Article
Language:	English
Published:	Dove Medical Press 2018-09-01
Series:	OncoTargets and Therapy
Subjects:	Pulmonary adenocarcinoma EGFR-T790M EGFR cis-C797S Drug resistance mechanisms
Online Access:	https://www.dovepress.com/effective-treatment-of-pulmonary-adenocarcinoma-harboring-triple-egfr--peer-reviewed-article-OTT

Similar Items

Combination of Osimertinib and Anlotinib May Overcome the Resistance Mediated by in cis EGFR T790M-C797S in NSCLC: A Case Report
by: Zhou R, et al.
Published: (2021-04-01)

Integrated Omics Analysis of Non-Small-Cell Lung Cancer Cells Harboring the EGFR C797S Mutation Reveals the Potential of AXL as a Novel Therapeutic Target in TKI-Resistant Lung Cancer
by: Tong-Hong Wang, et al.
Published: (2021-12-01)

Primary Resistance to Combination Therapy with First- and Third-Generation EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in Trans-C797S Mutations with Co-Occurring CTNNB1 Alteration
by: Chen J, et al.
Published: (2020-07-01)

Growth Suppression in Lung Cancer Cells Harboring EGFR-C797S Mutation by Quercetin
by: Kuo-Yen Huang, et al.
Published: (2021-08-01)

EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma
by: Chan Xiang, PhD, et al.
Published: (2021-07-01)

High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib
by: Atsushi Osoegawa, MD, PhD, et al.
Published: (2021-07-01)

Durable Clinical Response of Advanced Lung Adenocarcinoma Harboring EGFR-19del/T790M/BRAFV600E Mutations After Treating with Osimertinib and Dabrafenib Plus Trametinib: A Case Report
by: Ding H, et al.
Published: (2020-08-01)

Simultaneous Detection of the T790M and L858R Mutations in the <i>EGFR</i> Gene by Oligoribonucleotide Interference-PCR
by: Keisuke Baba, et al.
Published: (2019-08-01)

Differential MicroRNA Expression between T790M and L858R Mutated Lung Cancer
by: Ji Yeon Kim, et al.
Published: (2018-09-01)

Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first/second generation EGFR‐TKIs
by: Taira Ninomaru, et al.
Published: (2021-03-01)

Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme
by: Wei-Yun Lai, et al.
Published: (2014-01-01)

Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation
by: Changhui Li, et al.
Published: (2021-05-01)

Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma
by: Wang Yuli, et al.
Published: (2016-01-01)

Osimertinib Did Not Respond to a Pulmonary Adenocarcinoma with Triple Mutations of Epidermal Growth Factor Receptor, G719S, T790M and S768I
by: Seigo Minami, et al.
Published: (2019-02-01)

Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study
by: Peng D, et al.
Published: (2021-02-01)

Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib
by: Hanping Wang, et al.
Published: (2020-03-01)

Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report
by: Zhang Y, et al.
Published: (2018-12-01)

Machine Learning-Based CT Radiomics Analysis for Prognostic Prediction in Metastatic Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation Receiving Third-Generation EGFR-TKI Osimertinib Treatment
by: Xin Tang, et al.
Published: (2021-09-01)

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation
by: Akihiro Yoshimura, et al.
Published: (2019-03-01)

Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291)
by: Saad N, et al.
Published: (2017-03-01)

Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation
by: Hardy Niu, et al.
Published: (2017-09-01)

Acquired Drug Resistance Mechanism of Osimertinib in the Targeted Therapy of Non-small Cell Lung Cancer
by: Zitong ZHAO, et al.
Published: (2020-04-01)

Impact of the generation of EGFR‐TKIs administered as prior therapy on the efficacy of osimertinib in patients with non‐small cell lung cancer harboring EGFR T790M mutation
by: Yosuke Miyashita, et al.
Published: (2021-02-01)

Novel Selective and Potent EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer
by: Yanxia Li, et al.
Published: (2016-11-01)

Advanced Research on T790M Mutation in Non-small Cell Lung Cancer
by: Hui LI, et al.
Published: (2013-06-01)

Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real‐world clinical example
by: Bing Wei, et al.
Published: (2019-05-01)

Dynamic cfDNA Analysis by NGS in EGFR T790M-Positive Advanced NSCLC Patients Failed to the First-Generation EGFR-TKIs
by: Li Ma, et al.
Published: (2021-03-01)

Identification of Candidate Biomarkers for EGFR-T790M Drug-resistant  Gene Mutation in Advanced Lung Adenocarcinoma
by: Lijuan CHEN, et al.
Published: (2020-11-01)

The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations
by: Akihiro Yoshimura, et al.
Published: (2018-12-01)

Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group
by: Mariano Provencio, et al.
Published: (2021-03-01)

EGFR tyrosine kinase inhibitor HS-10182 increases radiation sensitivity in non-small cell lung cancers with EGFR T790M mutation
by: Yang Chen, et al.
Published: (2018-03-01)

AI-Based Drug Discovery of TKIs Targeting L858R/T790M/C797S-Mutant EGFR in Non-small Cell Lung Cancer
by: Geunho Choi, et al.
Published: (2021-07-01)

Acquisition of T790M resistance mutation in a patient with advanced adenocarcinoma harboring uncommon EGFR mutations: a case report and literature review
by: Hakozaki T, et al.
Published: (2019-01-01)

Resistance Profile of Osimertinib in Pre-treated Patients With EGFR T790M-Mutated Non-small Cell Lung Cancer
by: Maria Gabriela O. Fernandes, et al.
Published: (2021-05-01)

Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature
by: Klempner SJ, et al.
Published: (2017-12-01)

Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/ T790M/G796S) in cis
by: Balmanoukian, A.S, et al.
Published: (2022)

Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy
by: Isa Mambetsariev, et al.
Published: (2018-03-01)

The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
by: Cheng WC, et al.
Published: (2021-01-01)

Rebiopsy with Thoracoscopy under Local Anesthesia for the Detection of EGFR T790M Mutation
by: Asako Matsuda, et al.
Published: (2019-12-01)

Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
by: Kejing Tang, et al.
Published: (2019-02-01)

Cannot write session to /tmp/vufind_sessions/sess_7n9hi8kct1cbherh724l4a0aa9